Viridian Therapeutics, Inc.
VRDN
$19.23
$1.216.69%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -344.06M | -308.32M | -269.95M | -257.08M | -228.06M |
Total Depreciation and Amortization | 1.18M | 1.21M | 1.24M | 1.57M | 1.37M |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 28.38M | 26.66M | 26.79M | 43.78M | 50.72M |
Change in Net Operating Assets | 5.44M | 701.00K | 9.60M | 14.75M | 7.70M |
Cash from Operations | -309.06M | -279.75M | -232.32M | -196.99M | -168.26M |
Capital Expenditure | -535.00K | -597.00K | -511.00K | -445.00K | -556.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 28.73M | 15.05M | -228.14M | -335.00M | -202.18M |
Cash from Investing | 28.20M | 14.46M | -228.65M | -335.45M | -202.74M |
Total Debt Issued | -- | -- | -- | 0.00 | 15.00M |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 282.19M | 281.64M | 459.68M | 557.39M | 323.19M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | 25.00M | 25.00M | 25.00M | 101.19M | 76.19M |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -16.67M | -16.77M | -26.94M | -37.43M | -22.79M |
Cash from Financing | 290.52M | 289.87M | 457.74M | 621.15M | 391.59M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 9.66M | 24.57M | -3.23M | 88.72M | 20.59M |